DARE
NASDAQ · Pharmaceuticals
Dare Bioscience Inc
$1.40
+0.07 (+5.26%)
Financial Highlights (FY 2026)
Revenue
1.44M
Net Income
-18,760,385
Gross Margin
71.3%
Profit Margin
-1,300.7%
Rev Growth
-53.1%
D/E Ratio
2.42
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 71.3% | 71.3% | 44.5% | 44.5% |
| Operating Margin | -1,315.5% | -1,184.0% | 16.7% | 17.2% |
| Profit Margin | -1,300.7% | -1,235.6% | 17.9% | 15.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.44M | 3.08M | 6.37M | 6.18M |
| Gross Profit | 1.03M | 2.19M | 2.84M | 2.75M |
| Operating Income | -18,984,348 | -36,446,060 | 1.06M | 1.06M |
| Net Income | -18,760,385 | -36,016,097 | 1.14M | 939.3K |
| Gross Margin | 71.3% | 71.3% | 44.5% | 44.5% |
| Operating Margin | -1,315.5% | -1,184.0% | 16.7% | 17.2% |
| Profit Margin | -1,300.7% | -1,235.6% | 17.9% | 15.2% |
| Rev Growth | -53.1% | -53.1% | +7.5% | -4.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 7.48M | 7.48M | 9.41M | 9.16M |
| Total Equity | 3.08M | 3.08M | 13.13M | 13.27M |
| D/E Ratio | 2.42 | 2.42 | 0.72 | 0.69 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -16,686,506 | -33,814,378 | 1.58M | 1.73M |
| Free Cash Flow | — | — | 772.3K | 654.4K |